INT186115

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.42
Pain Relevance 0.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (EGFR) cell morphogenesis (EGFR) Golgi apparatus (EGFR)
endoplasmic reticulum (EGFR) intracellular (EGFR) enzyme binding (EGFR)
EGFR (Homo sapiens)
Pain Link Frequency Relevance Heat
Cannabinoid 18 96.48 Very High Very High Very High
palliative 4 93.28 High High
cINOD 34 71.16 Quite High
adenocard 1 69.16 Quite High
metalloproteinase 5 43.60 Quite Low
Inflammation 8 5.00 Very Low Very Low Very Low
Endocannabinoid 8 5.00 Very Low Very Low Very Low
antagonist 2 5.00 Very Low Very Low Very Low
COX2 2 5.00 Very Low Very Low Very Low
aspirin 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Prostate Cancer 21 99.84 Very High Very High Very High
Apoptosis 90 98.82 Very High Very High Very High
Noninfiltrating Intraductal Carcinoma 6 97.80 Very High Very High Very High
Carcinoma 25 96.76 Very High Very High Very High
Metastasis 27 91.84 High High
Thyroid Neoplasm 161 88.88 High High
Cancer 163 86.72 High High
Non-small-cell Lung Cancer 2 86.36 High High
Small Cell Lung Cancer 2 86.08 High High
Lung Cancer 47 80.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, inhibition of apoptosis with the broad specificity caspase inhibitor ZVAD did not prevent EGFR downregulation by sulindac metabolites.
Negative_regulation (prevent) of Negative_regulation (downregulation) of EGFR associated with apoptosis
1) Confidence 0.57 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.28 Pain Relevance 0.11
Down-regulation of COX-2, EGFR, p-EGFR and up-regulation of p21 and p27 were found in Ist-Mes-2, after treatment with single agents and in combination.
Negative_regulation (Down) of Negative_regulation (regulation) of EGFR
2) Confidence 0.37 Published 2010 Journal Mol Cancer Section Abstract Doc Link PMC2828989 Disease Relevance 0.57 Pain Relevance 0
These findings indicate that tyrosine kinase inhibitor (TKI) blockade of EGFR has potential in the treatment and chemoprevention of DCIS [47] (Table 1).
Negative_regulation (inhibitor) of Negative_regulation (blockade) of EGFR associated with noninfiltrating intraductal carcinoma
3) Confidence 0.36 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 0.97 Pain Relevance 0
In fact, the aforementioned compound ZD6474 is, in addition to its role in RTK inhibition, a potent and selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and EGFR.
Negative_regulation (inhibition) of Negative_regulation (inhibitor) of EGFR
4) Confidence 0.32 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 0.91 Pain Relevance 0.09
In cultured prostate cancer cells, down-regulation of epidermal growth factor receptor (EGFR) has been implicated in mediating the antiproliferative effect of the endogenous cannabinoid (CB) ligand anandamide.
Negative_regulation (down) of Negative_regulation (regulation) of epidermal growth factor receptor associated with cannabinoid and prostate cancer
5) Confidence 0.31 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC3009725 Disease Relevance 0.69 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox